A new article, “Impact of the COVID-19 Pandemic on Global Lung Cancer Clinical Trials: Why it matters to people with Lung Cancer,” has been accepted and published in the Journal of Thoracic Oncology Clinical and Research Reports. The piece follows a global study commissioned by International Association for the Study of Lung Cancer; adding the patient advocate voices of the Lung Cancer Research Foundation, LUNGevity Foundation, Roy Castle Lung Cancer Foundation, Lung Cancer Foundation of America, Lung Cancer Europe, and GO2 Foundation for Lung Cancer.

Only 2-8% of people with cancer participate in clinical trials, an issue which has only been exacerbated by the COVID-19 pandemic.

In the publication, the authors make recommendations for actions that stakeholders – regulatory agencies, non-pharmaceutical funders, and clinical trial investigators and sponsors – can implement long-term to increase access and remove barriers.

Representing LCRF as co-author is Eugene Manley, Jr., PhD, Director, Scientific Programs. Other co-authors are Upal Basu Roy, PhD, MPH, LUNGevity; Anne-Marie-Baird, PhD, Lung Cancer Europe; Andrew Ciupek, PhD, GO2 Foundation for Lung Cancer; Jesme Fox, MBChB, MBA, Roy Castle Lung Cancer Foundation); Kim Norris, Lung Cancer Foundation of America; Giorgio V. Scagliotti, MD, PhD; Heather A. Wakelee, MD; Tetsuya Mitsudomi, MD; Russell C. Clark, JD; Renee Arndt, MS; Fred R. Hirsch, MD, PhD; Paul A. Bunn, MD; and Matthew P. Smeltzer, PhD.

Download and read the article (PDF)